{"title":"Raising HDL-C through cholesteryl ester transfer protein inhibition","authors":"Adie Viljoen MMed, FRCPath, MBA, Anthony Wierzbicki DM, DPhil, FRCPath, FAHA","doi":"10.1002/fps.77","DOIUrl":null,"url":null,"abstract":"<p><b>Plasma concentrations of high-density lipoprotein cholesterol (HDL-C) and its major protein component apolipoprotein (apo) A-I are strongly inversely correlated with cardiovascular risk, leading to the notion that therapy to increase HDL-C and apoA-I concentrations would be antiatherosclerotic and protective against cardiovascular disease (CVD) events.1,2 In this article, the authors discuss how inhibition of cholesteryl ester transfer protein (CETP) could potentially lead to an increase in HDL-C with a subsequent reduction in CVD events, a hypothesis being tested by the development of the drugs anacetrapib and dalcetrapib.</b></p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 2","pages":"12-15"},"PeriodicalIF":0.0000,"publicationDate":"2011-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.77","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.77","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Plasma concentrations of high-density lipoprotein cholesterol (HDL-C) and its major protein component apolipoprotein (apo) A-I are strongly inversely correlated with cardiovascular risk, leading to the notion that therapy to increase HDL-C and apoA-I concentrations would be antiatherosclerotic and protective against cardiovascular disease (CVD) events.1,2 In this article, the authors discuss how inhibition of cholesteryl ester transfer protein (CETP) could potentially lead to an increase in HDL-C with a subsequent reduction in CVD events, a hypothesis being tested by the development of the drugs anacetrapib and dalcetrapib.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
